Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety and Tolerability Study of Agile AG200-15 Transdermal Contraceptive Delivery System

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy, sexually active woman at risk for pregnancy seeking to use hormonal contraception for at least 1 year~* Ability to demonstrate willingness to participate and adhere to study protocol~Exclusion Criteria:~* Known or suspected pregnancy~* Lactating women~* Anticipates use of condoms or any other form of back-up contraception during the study~* History of dermal sensitivity to medicated patches (nicotine) or to bandages, surgical tape, etc.~* Has a contraindication to combined estrogen-progestin contraceptive use~* Any disease that may worsen under hormonal treatment (cardiovascular, liver, metabolic)~* Smoker who is 35 years old or over

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- AG200-15 (Type: EXPERIMENTAL): AG200-15 is a transdermal delivery system designed to deliver daily hormone exposure of ethinyl estradiol (EE) and levonorgestrel (LNG)

Based on this trial design, predict the completion outcome and termination type (if applicable).